Goldman Sachs
INO icon

Goldman Sachs’s Inovio Pharmaceuticals INO Stock Holding History

Goldman Sachs’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
93,720
+48,996
+110% +$58.1K ﹤0.01% 6328
2026
Q1 		$77.8K Buy
44,724
+17,436
+64% +$28.7K ﹤0.01% 6240
2025
Q4 		$47.5K Sell
27,288
-26,423
-49% -$58.2K ﹤0.01% 6292
2025
Q3 		$126K Sell
53,711
-83,063
-61% -$159K ﹤0.01% 6044
2025
Q2 		$278K Buy
136,774
+6,240
+5% +$12K ﹤0.01% 5480
2025
Q1 		$213K Sell
130,534
-159,902
-55% -$321K ﹤0.01% 5614
2024
Q4 		$531K Buy
290,436
+217,246
+297% +$962K ﹤0.01% 5218
2024
Q3 		$423K Buy
73,190
+30,789
+73% +$254K ﹤0.01% 5141
2024
Q2 		$343K Buy
+42,401
New +$446K ﹤0.01% 5026
2024
Q1 		– Sell
-2,920
Closed -$214K – 5712
2023
Q4 		$214K Sell
2,920
-3,013
-51% -$14.9K ﹤0.01% 5125
2023
Q3 		$27.7K Sell
5,933
-17,481
-75% -$96.6K ﹤0.01% 5329
2023
Q2 		$125K Sell
23,414
-130,019
-85% -$1.05M ﹤0.01% 5315
2023
Q1 		$1.51M Buy
153,433
+8,725
+6% +$149K ﹤0.01% 4075
2022
Q4 		$2.71M Sell
144,708
-44,864
-24% -$1.02M ﹤0.01% 3691
2022
Q3 		$3.92M Buy
189,572
+65,500
+53% +$1.68M ﹤0.01% 3353
2022
Q2 		$2.58M Buy
124,072
+46,299
+60% +$1.3M ﹤0.01% 3825
2022
Q1 		$3.35M Sell
77,773
-66,004
-46% -$2.97M ﹤0.01% 3742
2021
Q4 		$8.61M Sell
143,777
-2,606
-2% -$209K ﹤0.01% 2910
2021
Q3 		$12.6M Buy
146,383
+37,924
+35% +$3.81M ﹤0.01% 2491
2021
Q2 		$12.1M Buy
108,459
+87,214
+411% +$8.38M ﹤0.01% 2512
2021
Q1 		$2.37M Buy
21,245
+5,740
+37% +$755K ﹤0.01% 3822
2020
Q4 		$1.65M Sell
15,505
-30,495
-66% -$4.06M ﹤0.01% 3859
2020
Q3 		$6.4M Buy
46,000
+1,583
+4% +$330K ﹤0.01% 2711
2020
Q2 		$14.4M Buy
44,417
+4,315
+11% +$693K ﹤0.01% 1953
2020
Q1 		$3.58M Buy
40,102
+24,871
+163% +$1.53M ﹤0.01% 2897
2019
Q4 		$603K Buy
15,231
+6,715
+79% +$202K ﹤0.01% 4397
2019
Q3 		$209K Sell
8,516
-678
-7% -$20.6K ﹤0.01% 4814
2019
Q2 		$324K Sell
9,194
-688
-7% -$27.3K ﹤0.01% 4592
2019
Q1 		$442K Sell
9,882
-7,601
-43% -$383K ﹤0.01% 4472
2018
Q4 		$839K Buy
17,483
+4,115
+31% +$250K ﹤0.01% 4066
2018
Q3 		$892K Buy
13,368
+870
+7% +$48.4K ﹤0.01% 4111
2018
Q2 		$588K Buy
12,498
+991
+9% +$54.7K ﹤0.01% 4413
2018
Q1 		$650K Buy
11,507
+4,086
+55% +$221K ﹤0.01% 4320
2017
Q4 		$368K Sell
7,421
-251
-3% -$15.6K ﹤0.01% 5045
2017
Q3 		$583K Sell
7,672
-7,823
-50% -$582K ﹤0.01% 4988
2017
Q2 		$1.46M Buy
15,495
+8,921
+136% +$763K ﹤0.01% 4113
2017
Q1 		$522K Sell
6,574
-2,747
-29% -$219K ﹤0.01% 4991
2016
Q4 		$776K Buy
9,321
+2,380
+34% +$215K ﹤0.01% 4673
2016
Q3 		$776K Buy
6,941
+2,951
+74% +$326K ﹤0.01% 4639
2016
Q2 		$442K Buy
3,990
+921
+30% +$112K ﹤0.01% 4959
2016
Q1 		$321K Buy
3,069
+2,518
+457% +$194K ﹤0.01% 5206
2015
Q4 		$44K Sell
551
-3,588
-87% -$286K ﹤0.01% 6604
2015
Q3 		$287K Sell
4,139
-8,338
-67% -$727K ﹤0.01% 5650
2015
Q2 		$1.22M Buy
12,477
+533
+4% +$56.9K ﹤0.01% 4347
2015
Q1 		$1.17M Sell
11,944
-10,962
-48% -$1.06M ﹤0.01% 4308
2014
Q4 		$2.52M Sell
22,906
-7,707
-25% -$942K ﹤0.01% 3610
2014
Q3 		$3.62M Sell
30,613
-9,024
-23% -$1.12M ﹤0.01% 3346
2014
Q2 		$5.14M Buy
39,637
+35,426
+841% +$4.18M ﹤0.01% 3011
2014
Q1 		$673K Sell
4,211
-17,443
-81% -$2.5M ﹤0.01% 5024
2013
Q4 		$3.01M Buy
+21,654
New +$2.17M ﹤0.01% 3629

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's INO Position: Q2 2026 in Review

Goldman Sachs increased its Inovio Pharmaceuticals (INO) stake by 110% in Q2 2026, buying an estimated $58.1K and bringing the position to 93,720 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #6328.

Goldman Sachs first reported a position in INO in Q4 2013 and has held it in 50 quarters since. The position peaked at $14.4M in Q2 2020. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Goldman Sachs held 93,720 shares of Inovio Pharmaceuticals worth $103K as of Q2 2026.
  • Goldman Sachs bought 48,996 Inovio Pharmaceuticals shares in Q2 2026, an estimated $58.1K.
  • Inovio Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6328 holding.
  • Goldman Sachs first reported a position in Inovio Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
  • Goldman Sachs's Inovio Pharmaceuticals position peaked at $14.4M in Q2 2020.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.